New drug cocktail shows promise for tough cancers

NCT ID NCT02734004

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see if the combination can shrink or stabilize tumors. About 264 participants are enrolled, and the study is no longer recruiting new patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (MEDI4736), olaparib, and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for patients with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm gastric adenocarcinoma gastric cancer gastric neoplasm Her2-receptor negative breast cancer ovarian cancer ovarian disorder small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST GASTRIC CANCERS OVARIAN SCLC

Contacts and locations

Locations

Research Site

Newnan, Georgia, 30265, United States
Research Site

Towson, Maryland, 21204, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Hilliard, Ohio, 43026, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Bordeaux, 33076, France
Research Site

Caen, 14076, France
Research Site

Clermont-Ferrand, 63011, France
Research Site

Dijon, 21079, France
Research Site

Marseille, 13385, France
Research Site

Nantes, 44202, France
Research Site

Paris, 75014, France
Research Site

Pierre Benit Cedex, 69495, France
Research Site

Toulouse, 31059, France
Research Site

Villejuif, 94805, France
Research Site

Haifa, 91096, Israel
Research Site

Jerusalem, 91031, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Tel Aviv, 6423906, Israel
Research Site

Amsterdam, 1066 CX, Netherlands
Research Site

Amsterdam, 1081 HV, Netherlands
Research Site

Maastricht, 6229 HX, Netherlands
Research Site

Nijmegen, 6525 GA, Netherlands
Research Site

Rotterdam, 3075 EA, Netherlands
Research Site

Utrecht, 3584 CX, Netherlands
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 135-710, South Korea
Research Site

Chur, CH-7000, Switzerland
Research Site

Lausanne, 1011, Switzerland
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Dundee, DD1 9SY, United Kingdom
Research Site

Glasgow, G12 0YN, United Kingdom
Research Site

Greater London, SW3 6JJ, United Kingdom
Research Site

London, NW1 2PG, United Kingdom
Research Site

London, SE1 9RY, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Newcastle upon Tyne, NE7 7DN, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.